801. Pegylated interferon-?2a treatment of chronic SIV-infected macaques
- Author
-
Richard B. Pollard, Christopher J. Miller, Satya Dandekar, David M. Asmuth, Michael D. George, and Kristina Abel
- Subjects
Simian Acquired Immunodeficiency Syndrome ,Alpha interferon ,Viremia ,Interferon alpha-2 ,Biology ,Virus Replication ,Antiviral Agents ,Peripheral blood mononuclear cell ,Article ,Polyethylene Glycols ,Immune system ,In vivo ,Pegylated interferon ,medicine ,Animals ,General Veterinary ,Monkey Diseases ,Interferon-alpha ,medicine.disease ,Virology ,Recombinant Proteins ,Viral replication ,Immunology ,Macaca ,Animal Science and Zoology ,Viral load ,medicine.drug - Abstract
Background In vitro and clinical observations in HIV-infected patients receiving interferon alpha therapy have shown a reduction in HIV loads. Limited investigations have explored the innate or adaptive immune responses of IFN-alpha on SIV replication in vivo. Methods Seven chronically infected rhesus macaques were given pegylated IFN-alpha 2a (n = four) or saline (n = three) injections once weekly for 14 weeks. Weekly peripheral blood samples were taken for safety parameters, viral load determinations, and measurements of innate and adaptive immune responses. Results Pharmacokinetic measurements demonstrated therapeutic peg-IFN-alpha levels for the initial period of therapy and IFN-alpha inducible antiviral molecules were increased sporadically in the PBMC mRNA of the treatment group. Despite the demonstrable effect of the IFN-alpha injections, the treatment had no effect on plasma viral RNA levels. Conclusions This work demonstrates that while short term IFN-alpha therapy induces innate antiviral immunity, it does not dramatically enhance or suppress viral replication. However, studies in the SIV model to determine therapeutic potential of chronic IFN-alpha therapy for the treatment of HIV will require macaque specific cytokines.
- Published
- 2007